PerkinElmer (PKI) and Its Competitors Head to Head Survey
PerkinElmer (NYSE: PKI) is one of 79 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its competitors? We will compare PerkinElmer to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.
This table compares PerkinElmer and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares PerkinElmer and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|PerkinElmer||$2.12 billion||$234.29 million||20.38|
|PerkinElmer Competitors||$2.14 billion||$229.91 million||-36.59|
PerkinElmer’s competitors have higher revenue, but lower earnings than PerkinElmer. PerkinElmer is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations for PerkinElmer and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PerkinElmer currently has a consensus target price of $68.23, indicating a potential downside of 6.99%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 10.81%. Given PerkinElmer’s higher probable upside, equities research analysts plainly believe PerkinElmer is more favorable than its competitors.
Risk and Volatility
PerkinElmer has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, PerkinElmer’s competitors have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. PerkinElmer pays out 7.8% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.5% of their earnings in the form of a dividend.
Institutional and Insider Ownership
90.5% of PerkinElmer shares are held by institutional investors. Comparatively, 50.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 2.2% of PerkinElmer shares are held by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
PerkinElmer beats its competitors on 8 of the 15 factors compared.
PerkinElmer Company Profile
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.